Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINIMA: Cemiplimab in Advanced HPV-related Head and Neck Cancer
NCT04988074Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2021
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in HPV-related head and neck squamous cell carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Dec 2021; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
HPV-related head and neck squamous cell carcinoma
Beyond the preview
Go deeper on NCT04988074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988074.